Metagenomi, Inc. (MGX)

Metagenomi Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	52.3	44.76	17.2	0.24
Revenue Growth (YoY)	16.84%	160.21%	6978.19%	-
Cost of Revenue	109.18	94.4	43.14	14.48
Gross Profit	-56.88	-49.65	-25.94	-14.24
Selling, General & Admin	32.02	28.85	18.7	9.71
Operating Expenses	32.02	28.85	18.7	9.71
Operating Income	-88.9	-78.49	-44.64	-23.95
Interest Expense	-	-	-0.1	-0.3
Interest & Investment Income	14.72	15.47	3.42	0.04
Other Non Operating Income (Expenses)	-0.21	-0.07	0.2	0
EBT Excluding Unusual Items	-74.39	-63.1	-41.12	-24.2
Gain (Loss) on Sale of Investments	-9.19	2.87	0.09	2.76
Pretax Income	-83.57	-60.23	-41.02	-21.44
Income Tax Expense	-5.51	8.03	2.57	-
Net Income	-78.06	-68.26	-43.59	-21.44
Net Income to Common	-78.06	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	33	3	3	6
Shares Outstanding (Diluted)	33	3	3	6
Shares Change (YoY)	870.10%	0.15%	-40.27%	-
EPS (Basic)	-2.36	-20.05	-12.82	-3.77
EPS (Diluted)	-2.36	-20.05	-12.82	-3.77
Free Cash Flow	-112.19	-101.22	15.75	21.35
Free Cash Flow Per Share	-3.40	-29.73	4.63	3.75
Gross Margin	-108.78%	-110.93%	-150.81%	-
Operating Margin	-170.00%	-175.38%	-259.53%	-9854.73%
Profit Margin	-149.27%	-152.50%	-253.45%	-8823.87%
Free Cash Flow Margin	-214.53%	-226.17%	91.55%	8787.65%
EBITDA	-83.49	-74.29	-42.91	-23.56
EBITDA Margin	-159.66%	-165.98%	-249.46%	-
D&A For EBITDA	5.41	4.21	1.73	0.39
EBIT	-88.9	-78.49	-44.64	-23.95
EBIT Margin	-170.00%	-175.38%	-259.53%	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q